Valuation: Laboratorio Reig Jofre SA

Market Cap 217M 0 253M 202M 186M 349M 24.21B 355M 2.38B 935M 12.15B 949M 929M 39.97B P/E 2026 *
13.3x
P/E 2027 * 22.2x
Enterprise Value 301M 0 352M 280M 259M 486M 33.68B 494M 3.32B 1.3B 16.91B 1.32B 1.29B 55.61B EV / Sales 2026 *
0.83x
EV / Sales 2027 * 0.75x
Free-Float
20.57%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 2005-12-31
Director of Finance/CFO - 2023-12-19
Chief Tech/Sci/R&D Officer - 2002-12-31
Director TitleAgeSince
Chairman - 2014-12-30
Director/Board Member 58 2014-12-30
Director/Board Member - 2017-11-06
Change 5-day change 1-year change 3-year change Capi.($)
+2.41%-.--% - - 250M
+4.46%+5.38%+83.42%+134.31% 1,093B
+0.85%+5.24%+55.13%+58.51% 653B
+2.72%+6.35%+28.76%+77.15% 458B
+1.80%-0.41%+43.52%+44.05% 355B
+1.24%+1.00%+26.84%+42.21% 294B
+2.07%+1.74%+2.66%+13.06% 248B
+4.02%+6.77%+51.17%+68.96% 230B
+1.05%-2.52%-13.83%-52.13% 203B
+2.90%+8.71%+25.10%+94.52% 178B
Average +1.91%+1.20%+33.64%+53.40% 412.27B
Weighted average by Cap. +1.35%+1.45%+47.89%+73.74%

Financials

2026 *2027 *
Net sales 365M 0 426M 340M 313M 588M 40.8B 598M 4.02B 1.58B 20.48B 1.6B 1.56B 67.35B 392M 0 458M 365M 336M 632M 43.82B 642M 4.32B 1.69B 21.99B 1.72B 1.68B 72.34B
Net income 16.7M 0 19.5M 15.55M 14.33M 26.92M 1.87B 27.37M 184M 72.1M 937M 73.22M 71.61M 3.08B 9.5M 0 11.09M 8.84M 8.15M 15.32M 1.06B 15.57M 105M 41.01M 533M 41.65M 40.73M 1.75B
Net Debt 84.7M 0 98.91M 78.85M 72.69M 137M 9.47B 139M 933M 366M 4.75B 371M 363M 15.63B 78.7M 0 91.9M 73.27M 67.54M 127M 8.8B 129M 867M 340M 4.42B 345M 337M 14.53B
Logo Laboratorio Reig Jofre SA
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
Employees
-
Trader
-
Investor
Global
-
Quality
ESG MSCI
-